Approximately 40% to 80% of patients receiving pertuzumab-directed therapy for human epidermal growth factor receptor 2 (HER2)-positive breast cancer will develop chemotherapy-induced diarrhea (CID). Loperamide and octreotide are frequently used to treat CID after diarrhea occurs, but neither is used prophylactically or targets the underlying mechanism. Previous studies suggest blocking epidermal growth factor receptor may cause excess chloride secretion, resulting in diarrhea. Crofelemer is derived from the red latex of the Croton lechleri tree, blocks gastrointestinal cystic fibrosis transmembrane regulator and calcium-activated chloride channels, and is U.S. Food and Drug Administration approved for relief of diarrhea in HIV/AIDS patients on anti-retroviral therapy. Crofelemer is not systemically absorbed, has relatively few side effects, and presents a targeted approach at preventing CID in patients receiving pertuzumabbased therapy. HALT-D (DiarrHeA Prevention and ProphyLaxis with Crofelemer in HER2-Positive Breast Cancer Patients Receiving Trastuzumab, Pertuzumab, and Docetaxel or Paclitaxel with or without Carboplatin, NCT02910219) is a phase II, randomized, open-label trial that aims to recruit 46 patients from 3 MedStar sites. Adults with HER2-positive breast cancer being treated with trastuzumab, pertuzumab, and docetaxel or paclitaxel (THP) or trastuzumab, pertuzumab, docetaxel, and carboplatin (TCHP) will be randomized to receive crofelemer or no medication for diarrhea prophylaxis. The primary endpoint is incidence of all grade diarrhea for 2 consecutive days during cycles 1 to 2 of THP or TCHP. Secondary endpoints include overall incidence, duration, and severity of diarrhea; time to onset of diarrhea; use of other anti-diarrheal medications; stool frequency and consistency; and quality of life. HALT-D will provide important information about the feasibility and tolerability of crofelemer in preventing diarrhea for patients receiving THP or TCHP.
Introduction
Approximately one-quarter of patients with breast cancer have human epidermal growth factor 2-positive (HER2 þ ) disease. 1 Pertuzumab-based regimens are U.S. Food and Drug Administration (FDA)-approved for use in the neoadjuvant and metastatic settings and are currently being studied in the adjuvant setting. [2] [3] [4] All grade chemotherapy-induced diarrhea (CID) is seen in up to 80% of patients, with 3% to 11.8% of patients who are receiving trastuzumab, pertuzumab, and docetaxel or paclitaxel (THP) or trastuzumab, pertuzumab, docetaxel, and carboplatin (TCHP) experiencing grade 3 and above diarrhea. [2] [3] [4] [5] But even grade 1 to pertuzumab-based regimens may be because of EGFR downregulation and blockade leading to excess chloride secretion and thus secretory diarrhea. [8] [9] [10] [11] [12] No anti-diarrheal medication used for the treatment of CID, including loperamide and octreotide, offers a targeted approach.
Crofelemer is an extract from the red latex of the Croton lechleri tree found in South America. 13 It is FDA-approved for treatment of diarrhea in HIV/AIDS patients on anti-retroviral therapy. 14 Crofelemer acts only luminally in the bowel owing to its size and polarity and is a dual inhibitor of the calcium-activated chloride channel and the cystic fibrosis transmembrane regulator, 2 of the 3 channels that control gastrointestinal chloride efflux. Given its mechanism of action, crofelemer may provide a targeted approach at preventing CID in patients with breast cancer receiving THP or TCHP chemotherapy. The primary aim of the HALT-D (NCT02910219) study is to compare the incidence of all-grade diarrhea for at least 2 consecutive days between patients who receive prophylaxis with crofelemer and those who do not receive any prophylactic medication, which is the current standard of care. Patients who will receive THP or TCHP for their breast cancer will be randomly assigned (1:1) to 1 of these 2 treatment arms and stratified to THP with docetaxel, THP with paclitaxel, or TCHP ( Figure 1 ). Diarrhea grading will be based on the National Cancer Institute Common Terminology Criteria for Adverse Events, v4.0.
HALT-D (
In addition to the incidence of all-grade diarrhea, HALT-D will also look at the duration of diarrhea, the time to onset to the first diarrhea episode, the use of anti-diarrhea rescue medications, stool frequency and consistency as measured by the Bristol Stool scale, and quality of life, as assessed by the Functional Assessment of Chronic Illness Therapy e Diarrhea (FACIT-D) total and diarrhea subset scores.
Treatment
Patients randomized to the crofelemer arm will receive crofelemer 125 mg twice daily during cycles 1 and 2 of THP or TCHP chemotherapy. During cycle 3, they will not receive crofelemer, but will still be followed for diarrhea. Patients randomized to the control arm will not receive any diarrhea prophylactic medication. However, patients in both arms are eligible to receive anti-diarrhea rescue medications (loperamide, tincture of opium, etc) should they develop diarrhea.
Key Inclusion Criteria
The study is open to male and female patients 18 years of age who have a pathologically confirmed diagnosis of HER2 
Key Exclusion Criteria
As HALT-D is seeking to determine the incidence of diarrhea, patients with ongoing irritable bowel syndrome or colitis or those with any type of ostomy, total colectomy, or fecal incontinence are excluded from the study. Furthermore, patients on active laxative, anti-diarrheal, antibiotic, anti-fungal, anti-parasite, or anti-viral medication use are excluded. Those who have radiation-induced bowel changes, are planning on receiving radiation therapy to the abdomen or pelvis while on study, or have had major abdominal or pelvic surgery within the past 6 months are excluded. Finally, patients with inadequate organ function for starting THP or TCHP will be excluded.
Statistical Considerations
A total of 46 patients will be accrued across 3 MedStar cancer sites in the greater Washington, DC area. The number and percent of patients who experience diarrhea of any grade for 2 or more consecutive days (felt to be definitely, probably, or possibly owing to THP or TCHP) during cycle 1 and 2 will be summarized with 2-sided 90% confidence interval overall and by treatment assignment, and compared between treatment arms using the Fisher exact test. The analysis population is defined as all randomized patients who complete 2 cycles of THP or TCHP chemotherapy.
We anticipate recruiting 2 to 3 patients per month across the study sites combined, with the accrual duration lasting approximately 17 to 26 months. We anticipate enrolling the first patient in October 2016. The last patient will be enrolled in the winter of 2018, with a final analysis completed in the spring of 2019.
Conclusions
Current CID guidelines recommend treating diarrhea with antidiarrheal medications such as loperamide or octreotide only after diarrhea develops. Very few studies have looked at preventing CID before it occurs. Crofelemer blocks chloride channels in the Clinical Breast Cancer February 2017 -77 gastrointestinal tract, potentially providing a targeted approach at preventing pertuzumab-mediated diarrhea. The HALT-D study has been designed to look at the efficacy of crofelemer in the prophylactic setting. This will be the first time crofelemer has been studied in conjunction with chemotherapy, and we hope the results from this trial can help contribute to the standard of care management of CID in patients with breast cancer.
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